Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1992 1
1993 1
1994 1
1998 1
2000 4
2001 1
2002 3
2003 1
2004 1
2007 2
2008 4
2009 1
2010 1
2012 1
2013 2
2014 2
2015 1
2016 1
2017 2
2018 2
2019 1
2020 3
2021 5
2022 4
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Adenoid cystic carcinoma. An indolent but aggressive tumour. Part B: treatment and prognosis.
Cantù G. Cantù G. Acta Otorhinolaryngol Ital. 2021 Aug;41(4):296-307. doi: 10.14639/0392-100X-N1729. Acta Otorhinolaryngol Ital. 2021. PMID: 34533533 Free PMC article. Review.
Anywhere the primary tumour is located, the most common treatment for ACC is complete surgical resection, with or without post-operative radiotherapy (PORT), while conventional photon and/or electron radiotherapy alone and chemotherapy are commonly used in unresectable or …
Anywhere the primary tumour is located, the most common treatment for ACC is complete surgical resection, with or without post-operative rad …
Pembrolizumab for the treatment of esophageal cancer.
Yamamoto S, Kato K. Yamamoto S, et al. Expert Opin Biol Ther. 2020 Oct;20(10):1143-1150. doi: 10.1080/14712598.2020.1792881. Epub 2020 Jul 14. Expert Opin Biol Ther. 2020. PMID: 32620063 Review.
INTRODUCTION: Esophageal cancer (EC) is the seventh most common cancer and the sixth leading cause of cancer death. However, the prognosis of unresectable advanced or recurrent EC patients remains poor and there are few effective therapeutic agents for EC. .. …
INTRODUCTION: Esophageal cancer (EC) is the seventh most common cancer and the sixth leading cause of cancer death. However, the prognosis o …
Chemotherapy in the management of squamous-cell carcinoma of the head and neck.
Lamont EB, Vokes EE. Lamont EB, et al. Lancet Oncol. 2001 May;2(5):261-9. doi: 10.1016/S1470-2045(00)00320-X. Lancet Oncol. 2001. PMID: 11905780 Review.
Previously reserved for palliation, chemotherapy is now also a central component of several curative approaches to the management of patients with advanced-stage head and neck cancer. Here we review the results of both induction chemotherapy and chemoradiotherapy tr …
Previously reserved for palliation, chemotherapy is now also a central component of several curative approaches to the management of patient …
Chemotherapy in the treatment of locally advanced head and neck cancer.
Forastiere AA. Forastiere AA. J Surg Oncol. 2008 Jun 15;97(8):701-7. doi: 10.1002/jso.21012. J Surg Oncol. 2008. PMID: 18493921 Review.
Three decades of collaborative research have led to the integration of platinum-based chemotherapy into the curative management of squamous cell carcinoma of the head and neck and gains in local-regional control, organ preservation and survival endpoints. ... …
Three decades of collaborative research have led to the integration of platinum-based chemotherapy into the curative management of squamous …
Management of locally advanced or unresectable head and neck cancer.
Culliney B, Birhan A, Young AV, Choi W, Shulimovich M, Blum RH. Culliney B, et al. Oncology (Williston Park). 2008 Sep;22(10):1152-61; discussion 1162-6, 1171-2. Oncology (Williston Park). 2008. PMID: 18935927 Free article. Review.
The treatment of patients with locoregionally advanced or unresectable squamous cell carcinoma of the head and neck is complex and associated with significant toxicities. ...In this article, we will review the available data regarding many of the ad …
The treatment of patients with locoregionally advanced or unresectable squamous cell carcinoma of the head and neck …
The discovery and development of vandetanib for the treatment of thyroid cancer.
Sim MW, Cohen MS. Sim MW, et al. Expert Opin Drug Discov. 2014 Jan;9(1):105-14. doi: 10.1517/17460441.2014.866942. Epub 2013 Dec 4. Expert Opin Drug Discov. 2014. PMID: 24299515 Review.
Although surgery remains effective for early-stage disease, patients with advanced disease pose a challenge as traditional therapies have not provided long-term benefits. ...This led to preclinical studies followed by recent human clinical trials, culminating in its …
Although surgery remains effective for early-stage disease, patients with advanced disease pose a challenge as traditional therapi …
Response-Adapted Treatment Following Radiotherapy in Patients With Resectable Locally Advanced Hypopharyngeal Carcinoma.
Luo X, Huang X, Liu S, Wang X, Luo J, Xiao J, Wang K, Qu Y, Chen X, Zhang Y, Wang J, Zhang J, Xu G, Gao L, Wu R, Yi J. Luo X, et al. JAMA Netw Open. 2022 Feb 1;5(2):e220165. doi: 10.1001/jamanetworkopen.2022.0165. JAMA Netw Open. 2022. PMID: 35191967 Free PMC article.
IMPORTANCE: Laryngeal preservation strategies for resectable locally advanced hypopharyngeal carcinoma (LAHPC) have been explored. ...A total of 250 patients with previous cancer history, synchronous primary cancer, stage I or II, or with unresectable …
IMPORTANCE: Laryngeal preservation strategies for resectable locally advanced hypopharyngeal carcinoma (LAHPC) have bee …
Vandetanib for the treatment of medullary thyroid cancer.
Chau NG, Haddad RI. Chau NG, et al. Clin Cancer Res. 2013 Feb 1;19(3):524-9. doi: 10.1158/1078-0432.CCR-12-2353. Epub 2012 Dec 11. Clin Cancer Res. 2013. PMID: 23231950 Review.
Vandetanib (ZD6474, Caprelsa, AstraZeneca), an oral small-molecule tyrosine kinase inhibitor (TKI) that targets the rearranged during transfection receptor (RET), VEGF receptor (VEGFR2-3), and EGF receptor (EGFR), is the first systemic therapy approved by the U.S. Food and …
Vandetanib (ZD6474, Caprelsa, AstraZeneca), an oral small-molecule tyrosine kinase inhibitor (TKI) that targets the rearranged during transf …
Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
Peris K, Licitra L, Ascierto PA, Corvò R, Simonacci M, Picciotto F, Gualdi G, Pellacani G, Santoro A. Peris K, et al. Future Oncol. 2015;11(4):703-12. doi: 10.2217/fon.14.281. Future Oncol. 2015. PMID: 25686123 Review.
Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Most occur on the head and neck, where cosmetic and functional outcomes are critical. ...Surgery is the treatment of choice for the majority of high-risk lesions. Aggressive, recurrent or unrese …
Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Most occur on the head and neck, where cosmetic and funct …
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Ferris RL, Harrington K, Schoenfeld JD, Tahara M, Esdar C, Salmio S, Schroeder A, Bourhis J. Ferris RL, et al. Cancer Treat Rev. 2023 Feb;113:102492. doi: 10.1016/j.ctrv.2022.102492. Epub 2022 Nov 30. Cancer Treat Rev. 2023. PMID: 36640618 Free article. Review.
Standard of care for patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) is surgery followed by chemoradiotherapy (CRT) or definitive CRT. ...IAPs have been shown to be overexpressed in SCCHN, are associated wi …
Standard of care for patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCH …
44 results